Welcome to CDC Stacks | HLA and risk of diffuse large B-cell lymphoma after solid organ transplantation - 42119 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
HLA and risk of diffuse large B-cell lymphoma after solid organ transplantation
  • Published Date:
    Nov 2016
  • Source:
    Transplantation. 100(11):2453-2460.


Public Access Version Available on: November 01, 2017 information icon
Please check back on the date listed above.
Details:
  • Personal Authors:
  • Pubmed ID:
    26636741
  • Pubmed Central ID:
    PMC4893345
  • Description:
    Background

    Solid organ transplant recipients have heightened risk for diffuse large B-cell lymphoma (DLBCL). The role of donor-recipient HLA mismatch and recipient HLA type on DLBCL risk are not well established.

    Methods

    We examined 172,231 U.S. kidney, heart, pancreas, and lung recipients transplanted between 1987 and 2010, including 902 with DLBCL. Incidence rate ratios (IRRs) were calculated using Poisson regression for DLBCL risk in relation to HLA mismatch, types, and zygosity, adjusting for sex, age, race/ethnicity, year, organ, and transplant number.

    Results

    Compared to recipients who had two HLA-DR mismatches, those with zero or one mismatches had reduced DLBCL risk, (zero: IRR=0.76, 95%CI=0.61–0.95; one: IRR=0.83, 95%CI=0.69–1.00). In stratified analyses, recipients matched at either HLA-A, -B, or -DR had a significantly reduced risk of late-onset (>2 years after transplantation), but not early-onset, DLBCL, and there was a trend for decreasing risk with decreasing mismatch across all three loci (P=0.0003). Several individual recipient HLA-A, -B, -C, -DR, and –DQ antigens were also associated with DLBCL risk, including DR13 (IRR=0.74, 95%CI=0.57–0.93) and B38 (IRR=1.48, 95%CI=1.10–1.93), confirming prior findings that these two antigens are associated with risk of infection-associated cancers.

    Conclusions

    In conclusion, variation in HLA is related to susceptibility to DLBCL, perhaps reflecting intensity of immunosuppression, control of Epstein-Barr virus infection among transplant recipients, or chronic immune stimulation.

  • Document Type:
    Journal Article
  • Collection(s):
    CDC Public Access
  • Funding:
    U58 DP003931/DP/NCCDPHP CDC HHS/United States
    K07 CA140360/CA/NCI NIH HHS/United States
    HHSN261201000037C/CA/NCI NIH HHS/United States
    N01PC35143/CA/NCI NIH HHS/United States
    HHSN261201000035C/PC,CA/None/None
    U58 DP003883/DP/NCCDPHP CDC HHS/United States
    U58 DP003875/DP/NCCDPHP CDC HHS/United States
    HHSN261201000036C/CA/NCI NIH HHS/United States
    U58 DP003879/DP/NCCDPHP CDC HHS/United States
    N01PC35137/CA/NCI NIH HHS/United States
    HHSN261201300071C/CA/NCI NIH HHS/United States
    U58 DP003920/DP/NCCDPHP CDC HHS/United States
    HHSN261201300011C/RC/CCR NIH HHS/United States
    U58 DP000807/DP/NCCDPHP CDC HHS/United States
    N01PC35142/CA/NCI NIH HHS/United States
    HHSN261201300021C/CA/NCI NIH HHS/United States
    HHSN261201000035I/CA/NCI NIH HHS/United States
    U58 DP000848/DP/NCCDPHP CDC HHS/United States
    HHSN261201000024C/CA/NCI NIH HHS/United States
    HHSN261201000034C/CA/NCI NIH HHS/United States
    U58 DP003921/DP/NCCDPHP CDC HHS/United States
    HHSN261201300011I/CA/NCI NIH HHS/United States
    U58 DP000832/DP/NCCDPHP CDC HHS/United States
    N01PC35139/CA/NCI NIH HHS/United States
    U58 DP000824/DP/NCCDPHP CDC HHS/United States
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States
    Personal Author:
    Gibson, Todd M.; Engels, Eric A.; Clarke, Christina A.; Lynch, Charles F.; Weisenburger, Dennis D.; Morton, Lindsay M.;
    Published:
    Apr 18 2014
    Source:
    Am J Hematol. 89(7):714-720.
    Description:
    Non-Hodgkin lymphoma arising in the context of immunosuppression is an important adverse outcome after solid organ transplantation. Diffuse large B-cell lymphoma (DLBCL) is the most commonly diagnosed subtype of post-transplantation non-Hodgkin lymph...
    File Type:
    Filetype[PDF - 331.46 KB]
  2. Risk of lymphoma subtypes after solid organ transplantation in the United States
    Personal Author:
    Clarke, C A; Morton, L M; Lynch, C; Pfeiffer, R M; Hall, E C; Gibson, T M; Weisenburger, D D; Martínez-Maza, O; Hussain, S K; Yang, J; Chang, E T; Engels, E A;
    Published:
    Jun 11 2013
    Source:
    Br J Cancer. 2013; 109(1):280-288.
    Description:
    Background: : Solid organ transplant recipients have high risk of lymphomas, including non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). A gap in our understanding of post-transplant lymphomas involves the spectrum and associated risks of their m...
    File Type:
    Filetype[PDF - 182.41 KB]
  3. Coming Soon
    Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era
    Personal Author:
    Tao, Li; Clarke, Christina A.; Rosenberg, Aaron S.; Advani, Ranjana H.; Jonas, Brian A.; Flowers, Christopher R.; Keegan, Theresa H.M.;
    Published:
    May 25 2017
    Source:
    Br J Haematol. 178(1):72-80.
    Description:
    With the addition of rituximab and other treatment advances, survival after diffuse large B-cell lymphoma (DLBCL) has improved, but subsequent primary malignancies (SPMs) have emerged as an important challenge for DLBCL survivorship. We calculated st...
    Public Access
    Available on:
    July 01, 2018
  4. Risk of myeloid neoplasms after solid organ transplantation
    Personal Author:
    Morton, Lindsay M.; Gibson, Todd M.; Clarke, Christina A.; Lynch, Charles F.; Anderson, Lesley A.; Pfeiffer, Ruth; Landgren, Ola; Weisenburger, Dennis D.; Engels, Eric A.;
    Published:
    Apr 14 2014
    Source:
    Leukemia. 28(12):2317-2323.
    Description:
    Solid organ transplant recipients have elevated cancer risks, owing in part to pharmacologic immunosuppression. However, little is known about risks for hematologic malignancies of myeloid origin. We linked the US Scientific Registry of Transplant Re...
    File Type:
    Filetype[PDF - 1.10 MB]
  5. Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and -uninfected patients in the pre-highly active antiretroviral therapy and pre-rituximab era
    Personal Author:
    Morton, Lindsay M.; Kim, Clara J.; Weiss, Lawrence M.; Bhatia, Kishor; Cockburn, Myles; Hawes, Debra; Wang, Sophia S.; Chang, Cindy; Altekruse, Sean F.; Engels, Eric A.; Cozen, Wendy;
    Published:
    Jul 29 2013
    Source:
    Leuk Lymphoma. 55(3):551-557.
    Description:
    Human immunodeficiency virus (HIV) infection substantially elevates diffuse large B-cell lymphoma (DLBCL) risk, but its impact on the distinct DLBCL subtypes defined by cell of origin is unclear. We compared DLBCL molecular characteristics and progno...
    File Type:
    Filetype[PDF - 309.58 KB]